english English    english 中文

Win-Win Fine Chemical Expert WINWIN Chemicals

Email: sales@win-winchemical.com

Hotline :0086-0577-64498589

Kyrva launched Novixid herbicides in India
win-win Industry news
Recently, Kyrva launched a new product Novixid herbicides (1.3%chloropyraidine +2.1%faw -sulfonamine) in a event at the event of Tyronnana, India. The event emphasizes the importance of weed management to improving crop output and farmers' profitability. Novixid is displayed as future technology. This product can effectively control ALS (acetyl lactase), ACCASE (acetyl olidase A carboxylase), HPPD (hydroxylphenyl acetonase), and weeds that have resistant to HPPD inhibitors. It also has good toxicology and ecological toxicology characteristics, which is good for soil health and environment. This makes Novixid as a unique product that effectively plays a role in various conditions and irrigation environments.
Read More...
The world's first! East China Pharmaceutical FRα target ADC new drug was approved for listing
win-win Industry news
On November 15, East China Pharmaceutical (000963.SZ) issued an announcement saying that American partner IMMUNOGEN, Inc. announced that it was used to treat the global FIRST-in-CLASS ADC drug Elahere ? (FIRST-In-Class) ADC (FIRST-In-Class) ADC (FIRT Mirvetuximab Soravtansine-GYNX, R & D code: IMGN853, HDM2002) obtained the Accelerated approval of the US Food and Drug Administration (FDA). Elahere ? has also become the first ADC drug approved by the FDA for platinum resistant ovarian cancer, which is used to treat folic acid receptor α (FRα) positive and previously accepted 1-3-line systemic treatment plan Adult patients with epithelial cancer, fallopian tube cancer or primary peritoneal cancer.
Read More...
2022 Diwali Festival
win-win Industry news
May Diwali bring you joy and success in 2022.
Read More...
Xianzhengda launched the pesticide MainSpring (bromyamide) for viewing plants in the UK
win-win Industry news
Recently, Xianzhengda launched the pesticides MainSpring at Jealott's Hill research base. This new type of wide -spectrum pesticide has been proven to be used to control the two main pests that can cause the protected ornamental plant to cause huge losses -caterpillar and thrips. , Add a vital new tool to the growers' weapon libraries. MainSpring's effective ingredient is bromylamide. The insecticide has a unique way to play in ornamental plant protection products, which can quickly and thoroughly play the effect.
Read More...
Haihe Pharmaceutical's Paclitaxel Oral Solution (RMX3001) China Marketing Authorization Application Officially Accepted
win-win Industry news
On September 13, 2022, Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and South Korea's Daehwa Pharmaceutical Co., Ltd. jointly announced that the paclitaxel oral solution jointly developed by the two parties has been officially accepted by the Center for Drug Evaluation of the State Drug Administration. The Chinese marketing application for this indication is mainly based on a randomized, open-label, parallel-controlled, non-inferiority design, multi-center Phase III clinical trial based on RMX3001/DHP107C2301, which aims to compare paclitaxel oral solution and paclitaxel injection in the second-line treatment of patients with advanced gastric cancer efficacy and safety. Professor Li Jin from Shanghai Oriental Hospital and Professor Qin Shukui from Nanjing Jinling Hospital jointly served as the principal investigators of the study. They said: "Paclitaxel oral solution adopts the patented self-emulsifying drug delivery technology, which has precise curative effect and avoids the common injection solvent Cremophor EL. some toxic and side effects, and easy to use.
Read More...
Hengrui Medicine: The first KRAS G12D inhibitor in China has been approved for clinical use!
win-win Industry news
On August 2, 2022, Hengrui Medicine issued an announcement that the company received the approval and issuance of the "Drug Clinical Trial Approval Notice" by the State Food and Drug Administration for HRS-4642 injection. HRS-4642 targets the KRAS G12D mutation and inhibits tumor cell proliferation. At present, no similar drugs have entered the clinic at home and abroad, and there is no relevant sales data. Therefore, Hengrui Medicine HRS-4642 is the first KRAS G12D inhibitor approved for clinical use in China. According to the statistics of Yaorong Cloud database, Hengrui Medicine HRS-4642 injection was undertaken by the Drug Application Center on May 20 this year, and it took 67 days to get the clinical approval.
Read More...
Page:1/ Total:7 First  Prev  Next  Last